Pacira BioSciences
PCRX
36.30
+11.10
+44.05%
Pacira BioSciences
US · PCRX
#3244 by market cap
36.30
+11.10
+44.05%
Live - 5344 symbols - heartbeat 22s ago
· 2026-10-08 10:11
Pre-market
36.33
+44.17%
After-hours
25.20
0.00%
Overnight
25.28
+0.32%
- Market cap
- 1.45B
- P/E (TTM)i
- 103.71
- P/Bi
- 2.15
- EPSi
- 0.16
- Div yieldi
- 0.00%
- 52W posi
- 100%
Reader sentiment
Are you bullish or bearish on PCRX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 114.14% -0.40pp
- Institutions
- 305
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund78.43%
Hedge Fund23.72%
Public Company8.64%
Individual/Insider2.21%
Government Pension Fund1.60%
Private Company0.69%
Bank/Investment Bank0.30%
Family Office/Trust0.27%
Insurance Company0.26%
Top holders as of 2026-06-30
BlackRock
16.82% · 6.71M sh
DOMA Perpetual Capital Management, LLC
6.97% · 2.78M sh
Vanguard Portfolio Management, LLC
6.04% · 2.41M sh
Dimensional Fund Advisors
5.28% · 2.10M sh
State Street Global Advisors
5.17% · 2.06M sh
Vanguard Capital Management, LLC
4.90% · 1.95M sh
D. E. Shaw & Co., L.P.
4.89% · 1.95M sh
Renaissance Technologies Corp.
4.35% · 1.73M sh
The Goldman Sachs Group, Inc.
2.95% · 1.17M sh
Geode Capital Management, LLC
2.91% · 1.16M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 23 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| David Stack | Chairperson & CEO | 0.60% |
| Shawn Cross | Chief Financial Officer | 0.26% |
| Frank Lee | Chief Executive Officer | 0.22% |
| Lauren Riker | Principal Accounting Officer & VP of Finance | 0.16% |
| Jonathan Slonin | Chief Clinical Officer | 0.16% |
| Charles Reinhart | Chief Financial Officer | 0.10% |
| Kristen Dunker | -- | 0.06% |
| Mark Kronenfeld | Independent Director | 0.05% |
| Laura Brege | Independent Director | 0.04% |
| Mark Froimson | Independent Director | 0.04% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-16 | Jonathan Slonin | Chief Clinical Officer | Automatic Disposition | -3,040 | $23.23 |
| 2026-06-11 | Abraham Ceesay | Independent Director | Intent to Sell (Form 144) | -9,039 | $23.27 |
| 2026-06-10 | Lauren Riker | Principal Accounting Officer & VP of Finance | Automatic Disposition | -6,115 | $23.50 |
| 2026-06-09 | Laura Brege | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Laura Brege | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Thomas Wiggans | Independent Director | Other Derivative Acquisition | +32,675 | $23.42 |
| 2026-06-09 | Christopher Christie | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Christopher Christie | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Alethia Young | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Alethia Young | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Marcelo Bigal | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Marcelo Bigal | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Mark Froimson | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Mark Froimson | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Michael Yang | Independent Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Michael Yang | Independent Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-09 | Samit Hirawat | Director | Other Acquisition | +6,405 | -- |
| 2026-06-09 | Samit Hirawat | Director | Other Derivative Acquisition | +10,891 | $23.42 |
| 2026-06-03 | Kristen Dunker | -- | Automatic Disposition | -10,259 | $22.27 |
| 2026-06-02 | Kristen Dunker | -- | Sale to Issuer | -8,528 | $22.32 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 10:11:31 · For reference only, not investment advice and not tailored to your situation.